Fate Therapeutics, Inc. (FATE) Dividend History

Company News

• Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

  Fate Therapeutics announced that clinical data from its ongoing Phase 1 trial of FT819, an off-the-shelf CAR T-cell product candidate, in patients with moderate-to-severe systemic lupus erythematosus (SLE) will be presented at the EULAR 2025 Congress.

  GlobeNewswire Inc.
• Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  Fate Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted restricted stock units representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee and granted under the Company's Amended and Restated Inducement Equity Plan.

  GlobeNewswire Inc.
• NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight

  The NK cell therapy market is experiencing significant growth, driven by rising interest in immuno-oncology and advancements in cell engineering technologies. Key players are investing in innovative approaches, including combination therapies and gene-modified NK cells, to improve clinical outcomes.

  GlobeNewswire Inc.

  Featured Companies: ARTV SNTI
• Fate Therapeutics Announces Leadership Transition

  Fate Therapeutics, a clinical-stage biopharmaceutical company, announced that Bob Valamehr, Ph.D. MBA, will assume the role of President and CEO on January 1, 2025, succeeding Scott Wolchko, who will retire after 10 years of leadership. The company will continue its mission to develop novel off-the-shelf cellular immunotherapies.

  GlobeNewswire Inc.
• Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

  Fate Therapeutics presented initial clinical and preclinical data for its CAR T-cell product candidate FT825 / ONO-8250, which targets HER2 and is designed to overcome on-target, off-tumor toxicity. The product showed a favorable safety profile and maintained an activated state in early-stage clinical trials.

  GlobeNewswire Inc.